Immuno Cure Kicks off Phase I Clinical Study of Therapeutic DNA Vaccine for HIV in Hong Kong

HONG KONG SAR – Immuno Cure BioTech, a leading biotechnology company, has announced the initiation of a Phase I clinical study of ICVAX, a therapeutic DNA vaccine for HIV. This groundbreaking study is being conducted in collaboration with the Faculty of Medicine of The Chinese University of Hong Kong (CUMedicine) and the AIDS Institute of Hong Kong.

The development of a safe and effective vaccine for HIV has been a long-standing goal in the medical community. With over 38 million people living with HIV globally, the need for a vaccine is more pressing than ever. Immuno Cure’s ICVAX is a promising candidate that has shown great potential in pre-clinical studies.

The Phase I clinical study will involve testing the safety and efficacy of ICVAX in a small group of healthy volunteers. This is an important first step in the vaccine development process and will provide crucial data for future studies. The study will be conducted at the CUMedicine Clinical Trials Centre, which is renowned for its state-of-the-art facilities and experienced medical team.

“We are thrilled to announce the initiation of our Phase I clinical study for ICVAX in Hong Kong,” said Dr. Liang Chen, CEO of Immuno Cure BioTech. “This is a significant milestone for our company and brings us one step closer to our goal of developing a safe and effective vaccine for HIV.”

The collaboration with CUMedicine brings together the expertise of both organizations in the field of HIV research. CUMedicine is a leading medical institution in Hong Kong and has a strong track record in conducting clinical trials for infectious diseases. The AIDS Institute of Hong Kong, which is part of CUMedicine, has been at the forefront of HIV research and treatment in the region.

“We are excited to be working with Immuno Cure on this important study,” said Professor David Chan, Dean of the Faculty of Medicine at CUMedicine. “This collaboration is a testament to our commitment to advancing medical research and finding solutions for global health challenges.”

ICVAX is a therapeutic DNA vaccine that works by stimulating the body’s immune system to produce antibodies against HIV. Unlike traditional vaccines, which use weakened or dead viruses, ICVAX uses a small piece of DNA that carries the genetic code for specific proteins found in HIV. This approach has shown promising results in pre-clinical studies and has the potential to be a game-changer in the fight against HIV.

The Phase I clinical study is expected to last for 12 months and will involve close monitoring of the volunteers’ health and immune response. If successful, the study will pave the way for larger-scale clinical trials and eventual approval for use in the general population.

“We are confident that ICVAX has the potential to be a breakthrough in the treatment of HIV,” said Dr. Chen. “We are committed to working closely with our partners at CUMedicine to bring this vaccine to those who need it most.”

The initiation of the Phase I clinical study for ICVAX in Hong Kong is a significant step forward in the fight against HIV. It is a testament to the dedication and hard work of the teams at Immuno Cure and CUMedicine, who are working tirelessly to find a cure for this devastating disease. With continued support and collaboration, we can hope for a future where HIV is no longer a threat to our global community.